Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.
暂无分享,去创建一个
R. Larson | M. Baccarani | C. Sawyers | A. Nagler | H. Kantarjian | T. Facon | A. Hochhaus | M. Voi | S. Goldberg | F. Cervantes | R. Ezzeddine